Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05061420
Title A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications

laryngeal squamous cell carcinoma

oral cavity cancer

hypopharynx cancer

head and neck squamous cell carcinoma

oral squamous cell carcinoma

Therapies

Cetuximab + Pembrolizumab + THOR-707

Cetuximab + THOR-707

Pembrolizumab + THOR-707

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.